Achilles Historical Financial Ratios
| ACHL Stock | USD 1.16 0.02 1.75% |
Achilles Therapeutics is presently reporting on over 82 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.27 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Achilles Therapeutics PLC financial condition quickly.
Achilles |
About Achilles Financial Ratios Analysis
Achilles Therapeutics PLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Achilles Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Achilles financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Achilles Therapeutics history.
Achilles Therapeutics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Achilles Therapeutics PLC dividend as a percentage of Achilles Therapeutics stock price. Achilles Therapeutics PLC dividend yield is a measure of Achilles Therapeutics stock productivity, which can be interpreted as interest rate earned on an Achilles Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Net Profit Margin
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.Most ratios from Achilles Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Achilles Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. At this time, Achilles Therapeutics' Income Quality is quite stable compared to the past year. Net Debt To EBITDA is expected to rise to 4.04 this year, although Book Value Per Share will most likely fall to 3.89.
| 2022 | 2023 | 2024 (projected) | PB Ratio | 0.18 | 0.25 | 0.29 | Capex To Depreciation | 2.04 | 0.23 | 0.27 |
Achilles Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Achilles Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Achilles Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 0.27 | 3.55 | 0.5 | 0.18 | 0.25 | 0.29 | |
| Book Value Per Share | 4.66 | 10.1 | 5.03 | 3.56 | 4.1 | 3.89 | |
| Free Cash Flow Yield | (0.0552) | (0.47) | (1.9) | (1.39) | (1.6) | (1.68) | |
| Operating Cash Flow Per Share | (0.62) | (2.07) | (1.52) | (1.21) | (1.09) | (1.15) | |
| Capex To Depreciation | 15.35 | 2.32 | 2.04 | 0.23 | 0.27 | 0.25 | |
| Pb Ratio | 0.27 | 3.55 | 0.5 | 0.18 | 0.25 | 0.29 | |
| Free Cash Flow Per Share | (0.91) | (2.34) | (1.71) | (1.24) | (1.12) | (1.17) | |
| Roic | (0.18) | (0.22) | (0.4) | (0.53) | (0.61) | (0.64) | |
| Net Income Per Share | (0.82) | (2.13) | (1.82) | (1.74) | (1.57) | (1.65) | |
| Days Of Inventory On Hand | 824.76 | 569.88 | 457.67 | 7.7E-5 | 8.9E-5 | 8.4E-5 | |
| Payables Turnover | 0.12 | 0.88 | 0.71 | 0.84 | 0.76 | 0.46 | |
| Cash Per Share | 4.38 | 9.29 | 4.43 | 3.29 | 3.78 | 3.6 | |
| Pocfratio | (26.62) | (2.42) | (0.59) | (0.73) | (0.66) | (0.69) | |
| Capex To Operating Cash Flow | (0.0666) | (0.47) | (0.13) | (0.0227) | (0.0204) | (0.0215) | |
| Pfcf Ratio | (18.12) | (2.15) | (0.53) | (0.72) | (0.65) | (0.68) | |
| Days Payables Outstanding | 3.0K | 413.23 | 513.39 | 434.26 | 499.4 | 474.43 | |
| Income Quality | 0.76 | 0.97 | 0.84 | 0.69 | 0.8 | 0.99 | |
| Roe | (0.18) | (0.21) | (0.36) | (0.49) | (0.56) | (0.59) | |
| Ev To Operating Cash Flow | (20.21) | 1.86 | 2.18 | 1.89 | 2.17 | 2.06 | |
| Pe Ratio | (20.25) | (2.35) | (0.49) | (0.51) | (0.46) | (0.48) | |
| Return On Tangible Assets | (0.15) | (0.19) | (0.32) | (0.43) | (0.5) | (0.52) | |
| Ev To Free Cash Flow | (13.76) | 1.65 | 1.93 | 1.84 | 2.12 | 2.02 | |
| Earnings Yield | (0.0494) | (0.43) | (2.02) | (1.96) | (2.25) | (2.14) | |
| Net Debt To E B I T D A | 4.91 | 4.4 | 2.1 | 1.8 | 2.07 | 4.04 | |
| Current Ratio | 11.3 | 14.9 | 10.93 | 8.57 | 9.85 | 15.18 | |
| Tangible Book Value Per Share | 4.66 | 10.11 | 5.04 | 3.56 | 4.1 | 3.89 | |
| Graham Number | 9.26 | 22.02 | 14.35 | 11.82 | 13.59 | 12.91 | |
| Shareholders Equity Per Share | 4.66 | 10.1 | 5.03 | 3.56 | 4.1 | 3.89 | |
| Capex Per Share | 0.29 | 0.27 | 0.19 | 0.0275 | 0.0316 | 0.0301 | |
| Graham Net Net | 3.81 | 8.71 | 4.2 | 3.01 | 3.46 | 3.29 | |
| Enterprise Value Over E B I T D A | (15.49) | 1.91 | 1.65 | 1.3 | 1.17 | 1.23 | |
| Price Earnings Ratio | (20.25) | (2.35) | (0.49) | (0.51) | (0.46) | (0.48) | |
| Operating Cycle | 824.76 | 569.88 | 457.67 | 7.7E-5 | 8.9E-5 | 8.4E-5 | |
| Price Book Value Ratio | 0.27 | 3.55 | 0.5 | 0.18 | 0.25 | 0.29 | |
| Price Earnings To Growth Ratio | 0.22 | (0.0147) | 0.034 | 0.12 | 0.13 | 0.0921 | |
| Days Of Payables Outstanding | 3.0K | 413.23 | 513.39 | 434.26 | 499.4 | 474.43 | |
| Price To Operating Cash Flows Ratio | (26.62) | (2.42) | (0.59) | (0.73) | (0.66) | (0.69) | |
| Price To Free Cash Flows Ratio | (18.12) | (2.15) | (0.53) | (0.72) | (0.65) | (0.68) | |
| Ebt Per Ebit | 1.02 | 0.98 | 0.95 | 0.91 | 0.92 | 1.06 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.